The studies identified genetic regions specifically associated with either oestrogen - receptor positive or
oestrogen receptor negative breast cancer, underscoring the fact that these are biologically distinct cancers that develop differently.
«A better understanding of the biological basis of
oestrogen receptor negative breast cancer may lead to more effective preventive interventions and treatments.»
«The study shows that long - term use of Tamoxifen does not increase incidence of breast cancer in the opposite breast, but it may increase the proportion of
oestrogen receptor negative cancers.
Not exact matches
Breast Cancer Care comment on claims that long - term use of Tamoxifen may increase proportion of
oestrogen receptor (ER)
negative cancers which develop in the opposite breast
Of these variants, reported today in the journals Nature and Nature Genetics, 65 are common variants that predispose to breast cancer and a further seven predispose specifically to
oestrogen -
receptor negative breast cancer - the subset of cases that do not respond to hormonal therapies, such as the drug tamoxifen.
However, not all cancer cells carry this
receptor - these are known as
oestrogen -
receptor negative.